Laurus Labs Limited (LAURUSLABS) - Net Assets
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has net assets worth Rs49.34 Billion INR (≈ $533.54 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs94.15 Billion ≈ $1.02 Billion USD) and total liabilities (Rs44.82 Billion ≈ $484.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Laurus Labs Limited to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs49.34 Billion |
| % of Total Assets | 52.4% |
| Annual Growth Rate | 27.09% |
| 5-Year Change | 76.97% |
| 10-Year Change | 440.32% |
| Growth Volatility | 26.92 |
Laurus Labs Limited - Net Assets Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see LAURUSLABS market cap overview.
Annual Net Assets for Laurus Labs Limited (2013–2025)
The table below shows the annual net assets of Laurus Labs Limited from 2013 to 2025. Also explore Laurus Labs Limited (LAURUSLABS) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs46.03 Billion ≈ $497.75 Million |
+11.83% |
| 2024-03-31 | Rs41.16 Billion ≈ $445.08 Million |
+1.65% |
| 2023-03-31 | Rs40.49 Billion ≈ $437.85 Million |
+20.53% |
| 2022-03-31 | Rs33.59 Billion ≈ $363.27 Million |
+29.16% |
| 2021-03-31 | Rs26.01 Billion ≈ $281.26 Million |
+46.95% |
| 2020-03-31 | Rs17.70 Billion ≈ $191.39 Million |
+13.56% |
| 2019-03-31 | Rs15.58 Billion ≈ $168.54 Million |
+5.11% |
| 2018-03-31 | Rs14.83 Billion ≈ $160.34 Million |
+11.44% |
| 2017-03-31 | Rs13.30 Billion ≈ $143.88 Million |
+56.19% |
| 2016-03-31 | Rs8.52 Billion ≈ $92.12 Million |
+18.17% |
| 2015-03-31 | Rs7.21 Billion ≈ $77.96 Million |
+101.12% |
| 2014-03-31 | Rs3.58 Billion ≈ $38.76 Million |
+38.23% |
| 2013-03-31 | Rs2.59 Billion ≈ $28.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Laurus Labs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5469.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs36.26 Billion | 81.08% |
| Common Stock | Rs1.08 Billion | 2.41% |
| Other Comprehensive Income | Rs53.80 Million | 0.12% |
| Other Components | Rs7.33 Billion | 16.39% |
| Total Equity | Rs44.73 Billion | 100.00% |
Laurus Labs Limited Competitors by Market Cap
The table below lists competitors of Laurus Labs Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guidewire Software Inc
NYSE:GWRE
|
$11.42 Billion |
|
Astra International Tbk
JK:ASII
|
$11.43 Billion |
|
Hero MotoCorp Limited
NSE:HEROMOTOCO
|
$11.44 Billion |
|
BJs Wholesale Club Holdings Inc
NYSE:BJ
|
$11.44 Billion |
|
S-Oil Corp
KO:010950
|
$11.41 Billion |
|
Fidelity National Financial Inc
NYSE:FNF
|
$11.40 Billion |
|
MILLICOM INTL CELL. DL15
F:M4M1
|
$11.39 Billion |
|
Metso Oyj
HE:METSO
|
$11.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laurus Labs Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 41,109,500,000 to 44,725,600,000, a change of 3,616,100,000 (8.8%).
- Net income of 3,583,200,000 contributed positively to equity growth.
- Dividend payments of 431,300,000 reduced retained earnings.
- Share repurchases of 101,700,000 reduced equity.
- New share issuances of 101,700,000 increased equity.
- Other comprehensive income increased equity by 342,500,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.58 Billion | +8.01% |
| Dividends Paid | Rs431.30 Million | -0.96% |
| Share Repurchases | Rs101.70 Million | -0.23% |
| Share Issuances | Rs101.70 Million | +0.23% |
| Other Comprehensive Income | Rs342.50 Million | +0.77% |
| Other Changes | Rs121.70 Million | +0.27% |
| Total Change | Rs- | 8.80% |
Book Value vs Market Value Analysis
This analysis compares Laurus Labs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 23.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 306.26x to 23.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-03-31 | Rs6.38 | Rs1954.00 | x |
| 2014-03-31 | Rs8.08 | Rs1954.00 | x |
| 2015-03-31 | Rs16.25 | Rs1954.00 | x |
| 2016-03-31 | Rs17.31 | Rs1954.00 | x |
| 2017-03-31 | Rs29.23 | Rs1954.00 | x |
| 2018-03-31 | Rs27.88 | Rs1954.00 | x |
| 2019-03-31 | Rs29.26 | Rs1954.00 | x |
| 2020-03-31 | Rs33.18 | Rs1954.00 | x |
| 2021-03-31 | Rs48.27 | Rs1954.00 | x |
| 2022-03-31 | Rs62.15 | Rs1954.00 | x |
| 2023-03-31 | Rs74.82 | Rs1954.00 | x |
| 2024-03-31 | Rs76.18 | Rs1954.00 | x |
| 2025-03-31 | Rs82.89 | Rs1954.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laurus Labs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.01%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.45%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 2.09x
- Recent ROE (8.01%) is below the historical average (16.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 34.02% | 12.28% | 1.02x | 2.71x | Rs622.88 Million |
| 2014 | 19.08% | 5.15% | 1.04x | 3.55x | Rs325.27 Million |
| 2015 | 9.48% | 5.15% | 0.72x | 2.56x | Rs-37.17 Million |
| 2016 | 15.70% | 7.52% | 0.77x | 2.70x | Rs485.53 Million |
| 2017 | 14.30% | 9.99% | 0.72x | 1.99x | Rs572.31 Million |
| 2018 | 11.30% | 8.15% | 0.68x | 2.03x | Rs193.46 Million |
| 2019 | 6.02% | 4.09% | 0.69x | 2.14x | Rs-620.77 Million |
| 2020 | 14.42% | 9.01% | 0.76x | 2.12x | Rs782.92 Million |
| 2021 | 37.87% | 20.43% | 0.84x | 2.21x | Rs7.24 Billion |
| 2022 | 24.69% | 16.77% | 0.71x | 2.08x | Rs4.92 Billion |
| 2023 | 19.57% | 13.08% | 0.79x | 1.90x | Rs3.86 Billion |
| 2024 | 3.91% | 3.18% | 0.60x | 2.04x | Rs-2.51 Billion |
| 2025 | 8.01% | 6.45% | 0.59x | 2.09x | Rs-889.36 Million |
Industry Comparison
This section compares Laurus Labs Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $55,732,551,119
- Average return on equity (ROE) among peers: 12.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laurus Labs Limited (LAURUSLABS) | Rs49.34 Billion | 34.02% | 0.91x | $11.41 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $354.09 Million | 3.07% | 2.25x | $31.32 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.00 Billion | 13.75% | 2.66x | $426.21 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $804.25 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $6.27 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $29.96 Billion | 21.83% | 0.26x | $4.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $33.31 Billion | 7.66% | 0.64x | $1.30 Billion |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $7.07 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.29 Billion | 15.52% | 0.29x | $154.33 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $52.38 Billion | 9.95% | 0.36x | $1.80 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $326.47 Billion | 10.68% | 0.52x | $10.79 Billion |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more